Abstract:Development of large, functional CD8+ T cell responses is crucial for successful cancer vaccine therapeutics. Neoantigens have demonstrated their potential as cancer vaccine immunogens, but improvements in delivery method are still necessary. In this work, we characterized five candidate Adenovirus Serotype 26 (Ad26) cancer vaccines for prophylactic efficacy in the MC-38 cancer model. All five single shot vaccines generated cellular immune responses at a higher level than prime boost peptide vaccination. The vaccines generated varying degrees of protection against tumor growth. The best Ad26 vaccine candidates showed improved protection compared to long synthetic peptide vaccines containing the same immunogens, the current standard in the field. Ad26 expressing seven neoantigens conjugated to the Herpes Viral Protein 22 (VP22) (Ad26.VP22.7Epi) was found to reduce tumor growth the most. Ad26.VP227Epi was compared to peptide vaccination in immune recall post challenge studies, in both the spleen and the tumor. Both Ad26.VP22.7Epi and Peptide showed a clear recall response after challenge in the spleen. This response was primarily focused on the Adpgk neoantigen but Ad26.VP22.7Epi additionally induced responses to the Irgq neoantigen while the peptide vaccine had stronger responses against the Reps1 neoantigen. The Ad26.VP227Epi vaccine generated increased numbers of infiltrating CD8+ T-cells, IFN+ CD8+ T-cells, and CD107a+ CD8+ T-cells, which all correlated with reduced tumor growth. We used single cell RNA-seq (scRNA-seq) to characterize tumor infiltrating lymphocyte populations (defined as CD45+) generated by the two platforms. We found that both Ad26.VP22.7Epi and Peptide induced higher numbers of infiltrating CD8+ T-cells within the tumor as compared to Sham. Single-cell analysis also showed higher numbers of tumor infiltrating Tregs in peptide vaccinated mice. Higher numbers of CD8+ T-cells correlated with protection as expected but interestingly increased numbers of Tregs positively correlated with tumor volume only among vaccinated mice, which could further explain differences between Ad vector and peptide vaccination. Differential gene expression analysis of CD8+ T-cells showed an upregulation of Th1 pathways and general T cell activation when comparing Ad vector vaccinated mice to peptide vaccinated. Peptide vaccinated CD8+ T-cells showed upregulation in the IL-10 pathway, potentially caused by an increased Tregs. Further investigation of these differences among CD8+ T cell and Treg populations could further elucidate potential mechanisms explaining the differences in platform efficacy. Citation Format: Gabriel Dagotto, Alessandro Colarusso, Robert Patio, David Li, Tochi Anioke, Victoria Giffin, Malika Aid, Dan Barouch. Neoantigen adenoviral cancer vaccine generates improved CD8+ T-cell responses compared to adjuvanted peptide vaccine [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy; 2023 Oct 1-4; Toronto, Ontario, Canada. Philadelphia (PA): AACR; Cancer Immunol Res 2023;11(12 Suppl) nr B004.

Nanovaccine impact on dendritic cells: transcriptome analysis enables new insights into antigen and adjuvant effects

Targeted Delivery of Nanovaccine to Dendritic Cells Via DC-Binding Peptides Induces Potent Antiviral Immunity in Vivo

Effective and Safe Stimulation of Humoral and Cell-Mediated Immunity by Intradermal Immunization with a Cyclic Dinucleotide/Nanoparticle Combination Adjuvant

Formulation, inflammation, and RNA sensing impact the immunogenicity of self-amplifying RNA vaccines

Uptake Quantification of Antigen Carried by Nanoparticles and Its Impact on Carrier Adjuvanticity Evaluation

Adjuvant Delivery Method and Nanoparticle Charge Influence Peptide Amphiphile Micelle Vaccine Bioactivity

The type of adjuvant strongly influences the T-cell response during nanoparticle-based immunization

Alpha-D-glucan nanoparticulate adjuvant induces a transient inflammatory response at the injection site and targets antigen to migratory dendritic cells

Dictating the spatial-temporal delivery of molecular adjuvant and antigen for the enhanced vaccination

Vaccination-Route-Dependent Adjuvanticity of Antigen-Carrying Nanoparticles for Enhanced Vaccine Efficacy

Distinct single-component adjuvants steer human DC-mediated T-cell polarization via Toll-like receptor signaling toward a potent antiviral immune response

Abstract 6743: Identifying new cellular adjuvants for cancer vaccines and immunotherapies

Intracellular signaling pathway in dendritic cells and antigen transport pathway in vivo mediated by an OVA@DDAB/PLGA nano-vaccine

Antigen transfer from non-APCs to APCs impacts the efficacy and safety of protein- and mRNA- based vaccines

Abstract B004: Neoantigen adenoviral cancer vaccine generates improved CD8+ T-cell responses compared to adjuvanted peptide vaccine

Adjuvant physiochemistry and advanced nanotechnology for vaccine development

A Toll-like Receptor-Activating, Self-Adjuvant Glycan Nanocarrier

Distinct pathways of humoral and cellular immunity induced with the mucosal administration of a nanoemulsion adjuvant

Self-Adjuvant Effect by Manipulating the Bionano Interface of Liposome-Based Nanovaccines

A molecular atlas of innate immunity to adjuvanted and live attenuated vaccines, in mice

The vaccine-site microenvironment: impacts of antigen, adjuvant, and same-site vaccination on antigen presentation and immune signaling